|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Clinical efficacy of the over-the-scope clip device: A systematic review显示文摘BACKGROUND The over-the-scope clip(OTSC)system has been increasingly utilized as a nonsurgical option to endoscopically manage refractory gastrointestinal(GI)hemorrhage,perforations/luminal defects and fistulas.Limited data exist evaluating the efficacy and safety of OTSC.AIM To determine the clinical success and adverse event(AE)rates of OTSC across all GI indications.METHODS A PubMed search was conducted for eligible articles describing the application of the OTSC system for any indication in the GI tract.Any article or case series reporting data for less than 5 total patients was excluded.The primary outcome was the rate of clinical success.Secondary outcomes included:Technical success rate,OTSC-related AE rate and requirement for surgical intervention despite-OTSC placement.Pooled rates(per-indication and overall)were calculated as the number of patients with the event of interest divided by the total number of patients.RESULTS A total of 85 articles met our inclusion criteria(n=3025 patients).OTSC was successfully deployed in 94.4%of patients(n=2856/3025).The overall rate of clinical success(all indications)was 78.4%(n=2371/3025).Per-indication clinical success rates were as follows:(1)86.0%(1120/1303)for GI hemorrhage;(2)85.3%(399/468)for perforation;(3)55.8%(347/622)for fistulae;(4)72.6%(284/391)for anastomotic leaks;(5)92.8%(205/221)for defect closure following endoscopic resection(e.g.,following endoscopic mucosal resection or endoscopic submucosal dissection);and(6)80.0%(16/20)for stent fixation.AE’s related to the deployment of OTSC were only reported in 64 of 85 studies(n=1942 patients),with an overall AE rate of 2.1%(n=40/1942).Salvage surgical intervention was required in 4.7%of patients(n=143/3025).CONCLUSION This systematic review demonstrates that the OTSC system is a safe and effective endoscopic therapy to manage GI hemorrhage,perforations,anastomotic leaks,defects created by endoscopic resections and for stent fixation.Clinical success in fistula management appears limited.Further studies,including randomized controlled trials comparing OTSC with conventional and/or surgical therapies,are needed to determine which indication(s)are the most effective for its use. | Nicholas Bartell Krystle Bittner Vivek Kaul Truptesh H Kothari Shivangi Kothari | 2020 | World Journal of Gastroenterology2020，26，24： | 5 |
| 2 | Prospective evaluation of the hemorrhoid energy treatment for the management of bleeding internal hemorrhoids显示文摘BACKGROUND The hemorrhoid energy treatment(HET)system is a non-surgical bipolar electrotherapy device,which has previously demonstrated efficacy in the management of bleeding Grade I and II internal hemorrhoids;however,data is limited.AIM To prospectively assess the safety and efficacy of the HET device.METHODS This was an IRB-approved prospective study of 73 patients with Grade I or II internal hemorrhoids who underwent HET from March 2016 to June 2019.Patient factors and procedural data were obtained.A post-procedure questionnaire was administered by telephone to all patients at 1-wk and 3-mo following HET to assess for improvement and/or resolution of rectal bleeding and adherence to a stool softener regimen.A chart review was performed to observe recurrent symptoms and durability of response.Statistical analyses were performed using SPSS software(IBM;SPSS Version 25.0).RESULTS Seventy-three patients underwent HET during the study period.Mean post-HET follow-up was 1.89 years.Complete resolution of bleeding was reported in 65%at 1 wk(n=48),with improvement in bleeding in 97.2%(n=71)of patients.At 3-mo,resolution and/or improvement in bleeding was reported in 90%(n=64)of patients.No procedure-related pain or adverse events were reported.CONCLUSION HET is well tolerated,safe and highly effective in the majority of our patients presenting with Grade I and II symptomatic internal hemorrhoids. | Truptesh H Kothari Krystle Bittner Shivangi Kothari Vivek Kaul | 2021 | World Journal of Gastrointestinal Endoscopy2021，13，8： | 2 |
| 3 | Recombinant human erythropoietin(rHEPO)loaded poly-(lactide-co-glycolide)microspheres:influence of theencapsulation technique and polymer purity on microspheres characteristics显示文摘 | BITTNER B MORLOCK M KOLL H G | 1998 | Eur J Pharm Biopharm1998，45，： | 1 |
| 4 | Impact of Solutol HS 15 on the pharmacokinetic behavior of midazolam upon intravenous administration to male Wistar rats 显示文摘 | Bittner B Bravo Gonzalez RC lsel H | 2003 | Eur J Pharm Biopharm2003，56，： | 1 |
| 5 | Expression profiling in cancer using cDNA microarrays显示文摘 | Khan J Saal L H Bittner M L | 1999 | Electrophoresis1999，20，2： | 1 |
| 6 | Prediction of mortality and morbidity with a 6 minute walk test in patients with left ventricular dysfunction 显示文摘 | Bittner V Weiner D H Yusuf S | 1993 | JAMA1993，270，14： | 1 |
| 7 | Relation between coal properties andacetylene yield in plasma pyrolysis 显示文摘 | Bittner D Baumann H Klein J | 1985 | Fuel1985，64，10： | 1 |
| 8 | Pyrolysis ofsome gaseous and liquid hydrocarbons in hydrogen plasma 显示文摘 | Beiers H G Baumann H Bittner D Klein J Jüntgen H | 1988 | Fuel1988，67，7： | 1 |
| 9 | Prediction of mortality and morbidity with 6-minute walk test in patients with left ventricular dysfunction显示文摘 | Bittner V Weiner D H Yusuf S | 1993 | JAMA1993，270，14： | 1 |
| 10 | Einsatz Schwerer Hobelanla-gen von der Innovation Zum Standard显示文摘 | Bittner M Weiss H J | 2007 | GlUckauf2007，143，78： | 1 |
| 11 | Pyrolysis of coal in hy- drogen and helium plasma显示文摘 | Baumann H Bittner D Beiers H G | 1988 | Fuel1988，67，8： | 1 |
| 12 | SOFIA primary mirror assembly:structural properties and optical performance显示文摘 | BITTNER H ERDMANN M HABERLER P | 2003 | SPIE2003，4857，： | 1 |
| 13 | Hydrides of La-Ni compounds 显示文摘 | Oesterreicher H Clinton J Bittner H | 1976 | Materials Research Bulletin1976，11，： | 1 |
| 14 | Hydride formation in La1-xMgxNi2 显示文摘 | Oesterreicher H Bittner H | 1980 | Journal of the Less-Common Metals1980，73，： | 1 |
| 15 | Hydrides of La--Ni compounds显示文摘 | OESTERREICHER H CLINTON J BITTNER H | 1976 | Materials Research Bulletin1976，11，10： | 1 |
| 16 | Matrix metalloproteinase - 9 activity is associated to oxidative stress in patients with acute coronary syndrome显示文摘 | Bittner A Alcalno H Castro PF | 2010 | Int J Cardiol2010，143，1： | 1 |
| 17 | Matrix metalloproteinase-9 activity is assoeiated to oxidative stress in patients with acute coronary syndrome显示文摘 | Bittner A Alcaino H Castro PF | 2010 | Int J Cardiol2010，143，1： | 1 |
| 18 | Myelin oligodendrocyte glycoprotein(MOG35 55)induced experimental autoimmune encephalomyelitis(EAE)in C57BL/6 mice显示文摘 | Bittner S Afzali AM Wiendl H | 2014 | J Vis Exp2014，15，51： | 1 |
| 19 | Remnant-like lipoproteins,hormone therapy,and angiographic and clinical outcomes:The Women's Angiographic Vitamin & Estrogen Trial显示文摘 | Bittner V Tripputi M Hsia J Gupta H Steffes M | 2004 | Am Heart J2004，148，2： | 1 |
| 20 | Lipid changes on hormone therapy and coronary heart disease events in the Heart and Estrogen/progestin Replacement Study (HERS)显示文摘 | Michael G Shlipak Lily A Chaput Eric Vittinghoff Feng Lin Vera Bittner Robert H Knopp Stephen B Hulley | 2003 | American Heart Journal2003，，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员